These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21827726)

  • 41. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
    Tornvall P; Nilsson T; Lagerqvist B
    J Intern Med; 2006 Oct; 260(4):363-8. PubMed ID: 16961673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The MULTISTRATEGY study].
    Danzi GB; Marzocchi A
    G Ital Cardiol (Rome); 2009 Jun; 10(6):353-7. PubMed ID: 19603605
    [No Abstract]   [Full Text] [Related]  

  • 43. Bleeding risks and vascular complications following abciximab therapy for percutaneous coronary intervention: a new look at an old problem.
    Kereiakes DJ; Broderick TM; Abbottsmith C; Shimshak TM
    J Invasive Cardiol; 2000 Feb; 12(2):95-8. PubMed ID: 10731271
    [No Abstract]   [Full Text] [Related]  

  • 44. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty.
    Garbarz E; Farah B; Vuillemenot A; André F; Angioï M; Machecourt J; Bassand JP; Wolf JE; Danchin N; Prendergast B; Iung B; Vahanian A
    Am J Cardiol; 1998 Sep; 82(6):800-3, A9. PubMed ID: 9761094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The FATA study].
    Merlini PA; Valgimigli M
    G Ital Cardiol (Rome); 2009 Jun; 10(6):358-63. PubMed ID: 19603606
    [No Abstract]   [Full Text] [Related]  

  • 46. Facilitated PCI: crossing the bridge with lessons learned.
    Mishra S; Bahl VK
    Indian Heart J; 2009; 61(5):410-2. PubMed ID: 20635753
    [No Abstract]   [Full Text] [Related]  

  • 47. Administering abciximab. A new drug for preventing coronary restenosis.
    Strimike CL; Wojcik JM
    Nursing; 1997 Mar; 27(3):32aa-32dd, 32ff. PubMed ID: 9171622
    [No Abstract]   [Full Text] [Related]  

  • 48. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
    Anderson KM; Bala MV; Weisman HF
    Am Heart J; 1999 May; 137(5):S129-32. PubMed ID: 10220615
    [No Abstract]   [Full Text] [Related]  

  • 49. Summary of recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.
    Montalescot G; Andersen HR; Antoniucci D; Betriu A; de Boer MJ; Grip L; Neumann FJ; Rothman MT
    Heart; 2004 Jun; 90(6):676-7. PubMed ID: 15145878
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacological facilitation of coronary intervention in ST-segment elevation myocardial infarction: time is of the essence.
    Gersh BJ; Stone GW
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1292-4. PubMed ID: 21232724
    [No Abstract]   [Full Text] [Related]  

  • 51. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in patients undergoing percutaneous coronary intervention.
    Kereiakes DJ
    Circulation; 2000 Dec; 102(25):E186. PubMed ID: 11120710
    [No Abstract]   [Full Text] [Related]  

  • 52. Abciximab, a novel platelet-blocking drug: pharmacology and nursing implications.
    Mayer DM; Docktor WJ
    Crit Care Nurse; 1998 Apr; 18(2):29-37. PubMed ID: 9708118
    [No Abstract]   [Full Text] [Related]  

  • 53. Facilitated percutaneous intervention following combination therapy with reteplase and abciximab for acute myocardial infarction.
    Weinstock BS
    J Invasive Cardiol; 2002 Feb; 14(2):100-4; quiz 104-5. PubMed ID: 11818648
    [No Abstract]   [Full Text] [Related]  

  • 54. Current coronary interventional practice.
    Hasdai D
    Cardiologia; 1998 Feb; 43(2):129-33. PubMed ID: 9557368
    [No Abstract]   [Full Text] [Related]  

  • 55. A new therapeutic monoclonal antibody.
    Freeman PR
    J Am Pharm Assoc (Wash); 1996 Feb; NS36(2):90-1. PubMed ID: 8742006
    [No Abstract]   [Full Text] [Related]  

  • 56. Primary percutaneous coronary intervention for acute MI: improving access and outcomes.
    Karha J; Hook MA; Brener SJ
    Cleve Clin J Med; 2005 Jul; 72(7):559-60, 562, 565-6 passim. PubMed ID: 16044653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is conventional antiplatelet therapy for the prevention of coronary stent thrombosis always safe? A case report of a patient with polycythemia vera.
    Zavalloni D; Marsico F; Milone F; Presbitero P
    Ital Heart J; 2004 Feb; 5(2):163-6. PubMed ID: 15086149
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.
    Ray KK
    Circulation; 2002 Mar; 105(12):e74. PubMed ID: 11914269
    [No Abstract]   [Full Text] [Related]  

  • 59. Counterintuitive contributions to the care of myocardial infarction and the need for randomized trials.
    Morrison DA
    J Am Coll Cardiol; 2003 Sep; 42(6):978-80. PubMed ID: 13678915
    [No Abstract]   [Full Text] [Related]  

  • 60. [The AIDA STEMI study].
    Prati F; Limbruno U
    G Ital Cardiol (Rome); 2013 Oct; 14(10):631-5. PubMed ID: 24121885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.